PCM
KURA icon

Prelude Capital Management’s Kura Oncology KURA Stock Holding History

Prelude Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,667
Closed -$521K – 1389
2024
Q3 		$521K Buy
26,667
+2,967
+13% +$60.1K 0.03% 613
2024
Q2 		$488K Buy
+23,700
New +$487K 0.03% 556
2021
Q1 		– Sell
-14,391
Closed -$470K – 1695
2020
Q4 		$470K Buy
14,391
+11,003
+325% +$387K 0.01% 744
2020
Q3 		$104K Buy
+3,388
New +$74.8K 0.01% 893
2018
Q1 		– Sell
-900
Closed -$14K – 1621
2017
Q4 		$14K Sell
900
-900
-50% -$13.3K ﹤0.01% 1173
2017
Q3 		$27K Buy
+1,800
New +$16.9K ﹤0.01% 1252
2016
Q1 		– Sell
-400
Closed -$3K – 1395
2015
Q4 		$3K Buy
+400
New +$3.15K ﹤0.01% 1367

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's KURA Position: Q4 2024 in Review

Prelude Capital Management sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 26,667 shares — an estimated $521K sold.

Prelude Capital Management first reported a position in KURA in Q4 2015 and held it in 7 quarters. The position peaked at $521K in Q3 2024. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

  • Prelude Capital Management reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 26,667 Kura Oncology shares in Q4 2024, an estimated $521K.
  • Prelude Capital Management first reported a position in Kura Oncology in Q4 2015 and held it in 7 quarters.
  • Prelude Capital Management's Kura Oncology position peaked at $521K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.